The overexpression of urokinase-type plasminogen activator receptors (uPARs) represents an established biomarker for aggressiveness in most common malignant diseases, including breast cancer (BC), prostate cancer (PC), and urinary bladder cancer (UBC), and is therefore an important target for new cancer therapeutic and diagnostic strategies. In this study, uPAR PET imaging using a 68Ga-labeled version of the uPAR-targeting peptide (AE105) was investigated in a group of patients with BC, PC, and UBC. The aim of this first-in-human, phase I clinical trial was to investigate the safety and biodistribution in normal tissues and uptake in tumor lesions. Methods: Ten patients (6 PC, 2 BC, and 2 UBC) received a single intravenous dose of 68Ga-NOTA-AE105 (154 ± 59 MBq; range, 48-208 MBq). The biodistribution and radiation dosimetry were assessed by serial whole-body PET/CT scans (10 min, 1 h, and 2 h after injection). Safety assessment included measurements of vital signs with regular intervals during the imaging sessions and laboratory blood screening tests performed before and after injection. In a subgroup of patients, the in vivo stability of 68Ga-NOTA-AE105 was determined in collected blood and urine. PET images were visually analyzed for visible tumor uptake of 68Ga-NOTA-AE105, and SUVs were obtained from tumor lesions by manually drawing volumes of interest in the malignant tissue. Results: No adverse events or clinically detectable pharmacologic effects were found. The radioligand exhibited good in vivo stability and fast clearance from tissue compartments primarily by renal excretion. The effective dose was 0.015 mSv/MBq, leading to a radiation burden of 3 mSv when the clinical target dose of 200 MBq was used. In addition, radioligand accumulation was seen in primary tumor lesions as well as in metastases. Conclusion: This first-in-human, phase I clinical trial demonstrates the safe use and clinical potential of 68Ga-NOTA-AE105 as a new radioligand for uPAR PET imaging in cancer patients.
The overexpression of urokinase-type plasminogen activator receptors (uPARs) represents an established biomarker for aggressiveness in most common malignant diseases, including breast cancer (BC), prostate cancer (PC), and urinary bladder cancer (UBC), and is therefore an important target for new cancer therapeutic and diagnostic strategies. In this study, uPAR PET imaging using a 68Ga-labeled version of the uPAR-targeting peptide (AE105) was investigated in a group of patients with BC, PC, and UBC. The aim of this first-in-human, phase I clinical trial was to investigate the safety and biodistribution in normal tissues and uptake in tumor lesions. Methods: Ten patients (6 PC, 2 BC, and 2 UBC) received a single intravenous dose of 68Ga-NOTA-AE105 (154 ± 59 MBq; range, 48-208 MBq). The biodistribution and radiation dosimetry were assessed by serial whole-body PET/CT scans (10 min, 1 h, and 2 h after injection). Safety assessment included measurements of vital signs with regular intervals during the imaging sessions and laboratory blood screening tests performed before and after injection. In a subgroup of patients, the in vivo stability of 68Ga-NOTA-AE105 was determined in collected blood and urine. PET images were visually analyzed for visible tumor uptake of 68Ga-NOTA-AE105, and SUVs were obtained from tumor lesions by manually drawing volumes of interest in the malignant tissue. Results: No adverse events or clinically detectable pharmacologic effects were found. The radioligand exhibited good in vivo stability and fast clearance from tissue compartments primarily by renal excretion. The effective dose was 0.015 mSv/MBq, leading to a radiation burden of 3 mSv when the clinical target dose of 200 MBq was used. In addition, radioligand accumulation was seen in primary tumor lesions as well as in metastases. Conclusion: This first-in-human, phase I clinical trial demonstrates the safe use and clinical potential of 68Ga-NOTA-AE105 as a new radioligand for uPAR PET imaging in cancerpatients.
Authors: Louise M Risør; Malene M Clausen; Zaza Ujmajuridze; Mohammed Farhadi; Kim F Andersen; Annika Loft; Jeppe Friborg; Andreas Kjaer Journal: J Nucl Med Date: 2021-12-02 Impact factor: 11.082
Authors: Jan-Philip Meyer; Paul Kozlowski; James Jackson; Kristen M Cunanan; Pierre Adumeau; Thomas R Dilling; Brian M Zeglis; Jason S Lewis Journal: J Med Chem Date: 2017-09-20 Impact factor: 7.446
Authors: Anders Christensen; Katalin Kiss; Giedrius Lelkaitis; Karina Juhl; Morten Persson; Birgitte Wittenborg Charabi; Jann Mortensen; Julie Lyng Forman; Anne Lyngholm Sørensen; David Hebbelstrup Jensen; Andreas Kjaer; Christian von Buchwald Journal: BMC Cancer Date: 2017-08-25 Impact factor: 4.430
Authors: Line Jee Hartmann Rasmussen; Martin Schultz; Anne Gaardsting; Steen Ladelund; Peter Garred; Kasper Iversen; Jesper Eugen-Olsen; Morten Helms; Kim Peter David; Andreas Kjaer; Anne-Mette Lebech; Gitte Kronborg Journal: Int J Cancer Date: 2017-04-24 Impact factor: 7.396
Authors: Esther Mena; Peter C Black; Soroush Rais-Bahrami; Michael Gorin; Mohamad Allaf; Peter Choyke Journal: World J Urol Date: 2020-07-15 Impact factor: 4.226
Authors: Christopher Montemagno; Shamir Cassim; Nicolas De Leiris; Jérôme Durivault; Marc Faraggi; Gilles Pagès Journal: Int J Mol Sci Date: 2021-06-15 Impact factor: 5.923
Authors: Olli Moisio; Senthil Palani; Jenni Virta; Petri Elo; Heidi Liljenbäck; Tuula Tolvanen; Meeri Käkelä; Maxwell G Miner; Erika Atencio Herre; Päivi Marjamäki; Tiit Örd; Merja Heinäniemi; Minna U Kaikkonen; Fenghua Zhang; Madduri Srinivasarao; Juhani Knuuti; Philip S Low; Antti Saraste; Xiang-Guo Li; Anne Roivainen Journal: Sci Rep Date: 2020-08-12 Impact factor: 4.379